Zimbabwe has declined a major American healthcare agreement valued at 367 million US dollars (£272m) spanning five years over Washington's insistence on confidential data.
This move came to light following a official document from December was leaked, indicating that President Emmerson Mnangagwa felt the arrangement was "unbalanced".
A government spokesman has since explained that the United States was requesting biological samples for research and commercial gain but was not willing to share the benefits from any future medical innovations.
"We are forced to start the difficult and regrettable task of scaling back our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had furnished more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has urged further talks to reach a agreement agreeable to all parties so the nation's vital HIV programme can continue.
Wider Background
This rejection follows a comparable situation in Kenya, where a high court suspended a similar deal with the US after concerns were raised about the safety of citizens' medical information.
After resuming the presidency recently, US President Donald Trump has slashed overseas assistance and shut down the US Agency for International Development (USAID).
The agency had administered assistance for the US government, but Trump stated its expenditure was "inefficient" and his administration was seeking direct bilateral deals to enhance transparency and accountability.
As per statements, 16 African countries have to date signed these new health pacts, constituting more than $18.3bn of fresh investment.
Details of the Rejected Deal
The money for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this partnership could have provided extraordinary benefits for Zimbabwean communities, especially the 1.2 million presently on HIV treatment through American-funded programmes," the Ambassador said.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"Zimbabwe was being asked to surrender its genetic material and health information indefinitely, with no equivalent guarantee of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that might result from that provided information," his statement read.
"Put simply, our country would supply the basic resources for scientific discovery without any certainty that the final treatments would be accessible to our population if a future pandemic emerge."
Sovereignty and Global Health
Mangwana further noted that the American exit from the global health body and its pursuit of bilateral deals were undermining structures already set up via the international health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing system created to deal with potential pandemics.
"This system is designed to guarantee that when a nation provides its samples, the benefits – such as vaccines and treatments – are shared equitably, not monopolised exclusively by those with the funds to develop them."
These objections regarding the US deal "must not be interpreted as anti-American sentiment," he added.
"We encourage further dialogue with our American counterparts on how future co-operation could be designed in a way that respects the sovereignty and dignity of each country."
Health Experts Response
Medical experts said it acknowledged the official position, but urged that talks must proceed considering a large portion of the country's HIV programmes depended on international support.
"In cases where specific concerns arise, including those involving data governance or implementation frameworks, these can frequently be addressed through technical clarification and negotiated safeguards," it commented.
This impasse underscores the continuing challenges between accepting crucial international aid and protecting national sovereignty in an increasingly data-driven world.